|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
NZ591087A
(en)
*
|
2008-10-01 |
2012-08-31 |
Micromet Ag |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
CA2738568C
(en)
*
|
2008-10-01 |
2024-02-20 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP3511342B1
(en)
|
2010-03-10 |
2024-01-17 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
TWI653333B
(zh)
*
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
AU2011261161A1
(en)
|
2010-06-01 |
2013-01-10 |
Ludwig Institute For Cancer Research Limited |
Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
|
|
WO2012006341A2
(en)
*
|
2010-07-06 |
2012-01-12 |
Aveo Pharmaceuticals, Inc. |
Anti-ron antibodies
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
RS67768B1
(sr)
|
2010-11-30 |
2026-03-31 |
Chugai Pharmaceutical Co Ltd |
Terapijski agens koji indukuje citotoksičnost
|
|
CN103261418A
(zh)
*
|
2010-12-10 |
2013-08-21 |
默克专利股份公司 |
介导肿瘤细胞裂解的双特异性适体
|
|
DE102011118022B4
(de)
*
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013078223A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Hospital & Research Center Oakland |
Anti-factor h binding protein antibodies and methods of use thereof
|
|
AR089114A1
(es)
|
2011-12-09 |
2014-07-30 |
Amgen Res Munich Gmbh |
PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
|
|
JP6284181B2
(ja)
*
|
2012-02-09 |
2018-02-28 |
国立研究開発法人理化学研究所 |
環状ｒｎａ及びタンパク質の製造方法
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
EP2708556B1
(en)
|
2012-09-12 |
2018-11-07 |
Samsung Electronics Co., Ltd |
Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
JO3519B1
(ar)
*
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
EP3447072A3
(en)
*
|
2013-03-05 |
2019-05-22 |
Baylor College of Medicine |
Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN103275225A
(zh)
*
|
2013-05-10 |
2013-09-04 |
洪建� |
高亲合力抗cd31/cd146双特异单克隆抗体及其应用
|
|
CN105899226B
(zh)
|
2013-10-14 |
2020-05-12 |
詹森生物科技公司 |
半胱氨酸工程化iii型纤连蛋白域结合分子
|
|
AU2014338864C1
(en)
|
2013-10-25 |
2020-07-16 |
Akamis Bio Limited |
Oncolytic adenoviruses armed with heterologous genes
|
|
CN106459990B
(zh)
|
2014-02-07 |
2021-06-01 |
麦克马斯特大学 |
三功能t细胞抗原偶联物及其制备方法和用途
|
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
|
|
CN118440206A
(zh)
|
2014-04-07 |
2024-08-06 |
中外制药株式会社 |
免疫活化抗原结合分子
|
|
EP3144388B1
(en)
*
|
2014-05-13 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirecting antigen-binding molecule for cells having immunosuppression function
|
|
WO2015172341A1
(zh)
*
|
2014-05-14 |
2015-11-19 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
|
BR112016030740A2
(pt)
|
2014-07-01 |
2018-02-20 |
Pfizer Inc. |
diacorpos heterodiméricos biespecíficos e seus usos
|
|
ES2743809T3
(es)
*
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
KR101615619B1
(ko)
*
|
2014-08-07 |
2016-04-26 |
주식회사 파멥신 |
c-Met 특이적 인간 항체 및 그 제조방법
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
EP3204416A1
(en)
*
|
2014-10-09 |
2017-08-16 |
EngMab AG |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
EP3204415B1
(en)
*
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
|
KR102309881B1
(ko)
|
2014-11-21 |
2021-10-06 |
삼성전자주식회사 |
c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
|
|
RU2020122439A
(ru)
*
|
2014-11-24 |
2020-09-24 |
Регенерон Фармасьютикалз, Инк. |
Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
CN110894240B
(zh)
|
2014-11-26 |
2022-04-15 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US20170096485A1
(en)
*
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
JP6968790B2
(ja)
*
|
2015-10-26 |
2021-11-17 |
ピエール、ファーブル、メディカマン |
Ｉｇｆ−１ｒ発現癌の処置のための組成物
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
CN106810610A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
|
CN106810611A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
|
TW201720458A
(zh)
*
|
2015-12-04 |
2017-06-16 |
宏觀基因股份有限公司 |
能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
|
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
|
|
EA201891022A1
(ru)
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
SI3468586T1
(sl)
|
2016-06-14 |
2025-01-31 |
Xencor, Inc. |
Bispecifična protitelesa za zaviralce kontrolnih točk
|
|
CA3029209A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
CN109476749A
(zh)
*
|
2016-06-30 |
2019-03-15 |
豪夫迈·罗氏有限公司 |
改良的过继性t细胞疗法
|
|
CN107573416A
(zh)
*
|
2016-06-30 |
2018-01-12 |
中国科学院深圳先进技术研究院 |
抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
|
|
TWI790206B
(zh)
*
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
CN119614520A
(zh)
*
|
2016-08-29 |
2025-03-14 |
阿卡米斯生物公司 |
携带双特异性t细胞衔接器的腺病毒
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
FI4050034T3
(fi)
|
2016-09-14 |
2024-06-10 |
Teneoone Inc |
Cd3:een sitoutuvia vasta-aineita
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
NZ754713A
(en)
|
2016-12-21 |
2025-11-28 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
JP7247110B2
(ja)
*
|
2017-06-05 |
2023-03-28 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
新規抗ｃｄ３抗体
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
IL271194B2
(en)
|
2017-06-20 |
2024-10-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
JP7009517B2
(ja)
|
2017-06-21 |
2022-01-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
KR102631281B1
(ko)
*
|
2017-08-10 |
2024-01-30 |
그리폴스 다이어그노스틱 솔루션즈 인크. |
재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
DE102017125150B4
(de)
*
|
2017-10-26 |
2019-10-10 |
Epiontis Gmbh |
Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
JP7144534B2
(ja)
*
|
2018-01-26 |
2022-09-29 |
重▲慶▼精准生物技▲術▼有限公司 |
改良されたヒンジ領域およびｃａｒ骨格の構築におけるその応用
|
|
WO2019195623A2
(en)
*
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
IT201800009282A1
(it)
*
|
2018-10-09 |
2020-04-09 |
Metis Prec Medicine Sb Srl |
Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
|
|
MY207205A
(en)
*
|
2018-12-07 |
2025-02-06 |
Shanghai hengrui pharmaceutical co ltd |
Cd3 antibody and pharmaceutical use thereof
|
|
TWI861039B
(zh)
|
2018-12-21 |
2024-11-11 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之促效cd28抗原結合分子
|
|
UA128825C2
(uk)
|
2019-03-01 |
2024-10-30 |
Ксенкор, Інк. |
Гетеродимерні антитіла, що зв'язують enpp3 та cd3
|
|
JP7776987B2
(ja)
|
2019-04-05 |
2025-11-27 |
テネオバイオ， インコーポレイテッド |
Ｐｓｍａに結合する重鎖抗体
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
WO2021050656A1
(en)
*
|
2019-09-11 |
2021-03-18 |
The Trustees Of The Univeristy Of Pennsylvania |
Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars)
|
|
CN115175920B
(zh)
|
2019-11-13 |
2025-10-31 |
阿穆尼克斯制药公司 |
加条形码的xten多肽及其组合物以及其制备和使用方法
|
|
CN114829408B
(zh)
*
|
2019-12-20 |
2024-01-26 |
山东博安生物技术股份有限公司 |
用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
|
|
EP4097135A4
(en)
*
|
2020-01-31 |
2024-07-03 |
Gensun Biopharma Inc. |
Bispecific t cell engagers
|
|
US20230075244A1
(en)
*
|
2020-02-20 |
2023-03-09 |
The Feinstein Institutes For Medical Research |
Agonist antibodies against endoglin and uses thereof
|
|
AU2021263448B2
(en)
|
2020-04-29 |
2026-02-05 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
US11834512B2
(en)
|
2020-05-04 |
2023-12-05 |
The Regents Of The University Of California |
Inhibiting anti-ENPP1 antibodies
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CN116406381A
(zh)
*
|
2020-05-19 |
2023-07-07 |
希望之城 |
工程化抗前列腺干细胞抗原融合蛋白及其用途
|
|
JP2023531494A
(ja)
|
2020-06-25 |
2023-07-24 |
アムニクス ファーマシューティカルズ， インコーポレイテッド |
Ｈｅｒ－２標的化二重特異性組成物ならびにその作製および使用のための方法
|
|
WO2022002112A1
(en)
|
2020-07-01 |
2022-01-06 |
Shandong Boan Biotechnology Co., Ltd. |
Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
CN112063608B
(zh)
*
|
2020-08-27 |
2022-06-17 |
浙江工业大学 |
一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
CA3173810A1
(en)
|
2021-06-01 |
2022-12-01 |
Andreas Bader |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CN115536740A
(zh)
*
|
2021-06-30 |
2022-12-30 |
苏州方德门达新药开发有限公司 |
介导细胞内有效滞留cd3的空间构象表位及其应用
|
|
MX2024006079A
(es)
*
|
2021-11-19 |
2024-07-29 |
Wuhan Yzy Biopharma Co Ltd |
Anticuerpo biespecifico y uso del mismo.
|
|
US20240165213A1
(en)
*
|
2022-11-21 |
2024-05-23 |
Avstera Therapeutics Corp. |
mRNA COMPOSITION FOR PREVENTING AND TREATING CANCER
|
|
CN121426967A
(zh)
|
2023-02-10 |
2026-01-30 |
阿穆尼克斯制药公司 |
靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
|
|
EP4683718A1
(en)
|
2023-04-17 |
2026-01-28 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting epidermal growth factor receptor and methods for making and using the same
|
|
CN116790744B
(zh)
*
|
2023-06-30 |
2024-04-26 |
浙江大学 |
一种缺血性心脏病晚期纤维化干预靶点及其应用
|
|
TW202534086A
(zh)
*
|
2024-02-28 |
2025-09-01 |
香港商Ｆｂｄ生物製劑有限公司 |
抗ｐｓｃａ抗體及其用途
|
|
WO2026024863A2
(en)
|
2024-07-24 |
2026-01-29 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
|